|
|
|
| 
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
|
Aprea Therapeutics, Inc. (APRE) |
|
|
$0.00 0.00 (0.00%) as of 4:30 Fri 2/14
|
|
Download |
|
|
| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
20,990,000 |
| Market
Cap: |
N/A |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0 - $0 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Aprea Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing cancer therapeutics that reactivate mutant p53 tumor suppressor protein. p53 is the protein expressed from the TP53 gene, a mutated gene in cancer. Co.'s main product candidate, APR-246, or eprenetapopt, is a small molecule p53 reactivator that is in clinical development for hematologic malignancies, including myelodysplastic syndromes (MDS) and acute myeloid leukemia. Co. is conducting several trials in hematologic malignancy indications, including a trial of eprenetapopt with azacitidine for frontline treatment of TP53 mutant MDS.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
16,730 |
16,730 |
26,827 |
114,327 |
| Total Buy Value |
$121,961 |
$121,961 |
$158,917 |
$218,541 |
| Total People Bought |
4 |
4 |
4 |
5 |
| Total Buy Transactions |
4 |
4 |
6 |
8 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-01-14 |
2023-10-13 |
2023-04-14 |
2022-04-14 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Hamill John P. |
SrVP/CFO/Prin Fin & Acct Ofcr |
• – – |
2024-03-28 |
4 |
A |
$0.00 |
$0 |
D/D |
3,365 |
18,868 |
|
- |
|
| Gilad Oren |
President, CEO |
• • – |
2024-03-28 |
4 |
A |
$0.00 |
$0 |
D/D |
6,725 |
331,495 |
|
- |
|
| Henneman John B III |
Director |
– • – |
2024-03-13 |
4 |
B |
$7.29 |
$50,009 |
D/D |
6,860 |
8,139 |
2.39 |
- |
|
| Seizinger Bernd R. |
Director |
– • – |
2024-03-13 |
4 |
B |
$7.29 |
$50,009 |
D/D |
6,860 |
33,685 |
2.39 |
- |
|
| Hamill John P. |
SrVP/CFO/Prin Fin & Acct Ofcr |
• – – |
2024-03-13 |
4 |
B |
$7.29 |
$7,363 |
D/D |
1,010 |
15,503 |
2.74 |
- |
|
| Gilad Oren |
President, CEO |
• • – |
2024-03-13 |
4 |
B |
$7.29 |
$14,580 |
D/D |
2,000 |
324,770 |
2.81 |
- |
|
| Pamukcu Rifat |
Director |
– • – |
2023-08-23 |
4 |
A |
$0.00 |
$0 |
D/D |
500 |
3,356 |
|
- |
|
| Seizinger Bernd R. |
Director |
– • – |
2023-08-23 |
4 |
A |
$0.00 |
$0 |
D/D |
500 |
26,825 |
|
- |
|
| Duey Marc |
Director |
– • – |
2023-08-23 |
4 |
A |
$0.00 |
$0 |
D/D |
500 |
208,878 |
|
- |
|
| Grissinger Michael |
Director |
– • – |
2023-08-23 |
4 |
A |
$0.00 |
$0 |
D/D |
500 |
799 |
|
- |
|
| Peters Richard |
Director |
– • – |
2023-08-23 |
4 |
A |
$0.00 |
$0 |
D/D |
500 |
1,029 |
|
- |
|
| Henneman John B III |
Director |
– • – |
2023-08-23 |
4 |
A |
$0.00 |
$0 |
D/D |
500 |
1,279 |
|
- |
|
| Seizinger Bernd R. |
Director |
– • – |
2023-06-07 |
4 |
B |
$3.68 |
$22,192 |
D/D |
6,029 |
26,325 |
2.39 |
- |
|
| Seizinger Bernd R. |
Director |
– • – |
2023-06-06 |
4 |
B |
$3.63 |
$14,764 |
D/D |
4,068 |
20,296 |
2.39 |
- |
|
| Gilad Oren |
President, CEO |
• • – |
2023-03-09 |
4 |
A |
$0.00 |
$0 |
D/D |
4,000 |
322,770 |
|
- |
|
| Hamill John P. |
SrVP/CFO/Prin Fin & Acct Ofcr |
• – – |
2023-02-27 |
4 |
A |
$5.25 |
$5,250 |
D/D |
1,000 |
14,493 |
|
- |
|
| Hamill John P. |
SrVP/CFO/Prin. Fin&Acctg. Off |
• – – |
2023-01-30 |
4 |
A |
$0.00 |
$0 |
D/D |
269,879 |
269,879 |
|
- |
|
| Pamukcu Rifat |
Director |
– • – |
2022-08-23 |
4 |
A |
$0.00 |
$0 |
I/I |
271,870 |
14,108 |
|
- |
|
| Pamukcu Rifat |
Director |
– • – |
2022-08-23 |
4 |
A |
$0.00 |
$0 |
D/D |
49,280 |
57,142 |
|
- |
|
| Duey Marc |
Director |
– • – |
2022-08-23 |
4 |
A |
$0.00 |
$0 |
I/I |
11,610 |
602 |
|
- |
|
| Duey Marc |
Director |
– • – |
2022-08-23 |
4 |
A |
$0.00 |
$0 |
D/D |
4,009,690 |
4,167,589 |
|
- |
|
| Gilad Oren |
President, CEO |
• • – |
2022-08-23 |
4 |
A |
$0.00 |
$0 |
D/D |
6,045,100 |
6,375,414 |
|
- |
|
| Peters Richard |
Director |
– • – |
2022-07-28 |
4 |
A |
$0.00 |
$0 |
D/D |
5,995 |
10,605 |
|
- |
|
| Grissinger Michael |
Director |
– • – |
2022-07-28 |
4 |
A |
$0.00 |
$0 |
D/D |
5,995 |
5,995 |
|
- |
|
| Seizinger Bernd R. |
Director |
– • – |
2022-07-28 |
4 |
A |
$0.00 |
$0 |
D/D |
5,995 |
324,575 |
|
- |
|
126 Records found
|
|
Page 1 of 6 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
